Clioquinol and other hydroxyquinoline derivatives inhibit Aβ(1-42) oligomer assembly

Neuroscience Letters

Volumn 465, Issue 1, 2009, Pages 99-103

  LeVine III, Harry ^a   Ding, Qunxing ^b   Walker, John A ^c   Voss, Randal S ^c   Augelli Szafran, Corinne E ^d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b KENT STATE UNIVERSITY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

Author keywords

Amyloid; Biotin; Crosslinking; ELISA; PICUP; Robotic screening

Indexed keywords

8 QUINOLINOL; 8 QUINOLINOL DERIVATIVE; AMYLOID BETA PROTEIN[1-42]; CLIOQUINOL; PBT 1; PBT 2; PLACEBO; QUINOLINOL DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BLINDNESS; CHELATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG SCREENING; DRUG STRUCTURE; HUMAN; IC 50; NONHUMAN; OLIGOMERIZATION; PARALYSIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTOZOAL INFECTION;

AMYLOID BETA-PROTEIN; ANTIPROTOZOAL AGENTS; AVIDIN; BIOTINYLATION; CHELATING AGENTS; CLIOQUINOL; DRUG EVALUATION, PRECLINICAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HYDROXYQUINOLINES; PEPTIDE FRAGMENTS; PROTEIN MULTIMERIZATION; SMALL MOLECULE LIBRARIES;

EID: 70349142176     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.08.002     Document Type: Article

References (39)

1. Adlard P.A., Cherny R.A., Finkelstein D.I., Gautier E., Robb E., Cortes M., Volitakis I., Liu X., Smith J.P., Perez K., Laughton K., Li Q.X., Charman S.A., Nicolazzo J.A., Wilkins S., Deleva K., Lynch T., Kok G., Ritchie C.W., Tanzi R.E., Cappai R., Masters C.L., Barnham K.J., and Bush A.I. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59 (2008) 43-55
2. Bitan G., Kirkitadze M.D., Lomakin A., Vollers S.S., Benedek G.B., and Teplow D.B. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 330-335
3. Bitan G., Lomakin A., and Teplow D.B. Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem. 276 (2001) 35176-35184
4. Bitan G., and Teplow D.B. Rapid photochemical cross-linking-a new tool for studies of metastable, amyloidogenic protein assemblies. Acc. Chem. Res. 37 (2004) 357-364
5. Bitan G., Vollers S.S., and Teplow D.B. Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. J. Biol. Chem. 278 (2003) 34882-34889
6. Bush A.I. Drug development based on the metals hypothesis of Alzheimer's disease. J. Alzheimers Dis. 15 (2008) 223-240
7. Cahoon L. The curious case of clioquinol. Nat. Med. 15 (2009) 356-359
8. Deraeve C., Pitie M., Mazarguilb H., and Meunierz B. Bis-8-hydroxyquinoline ligands as potential anti-Alzheimer agents. New J. Chem. 31 (2007) 193-195
9. Findeis M.A. Peptide inhibitors of beta amyloid aggregation. Curr. Top. Med. Chem. 2 (2002) 417-423
10. Gellermann G.P., Byrnes H., Striebinger A., Ullrich K., Mueller R., Hillen H., and Barghorn S. A beta-globulomers are formed independently of the fibril pathway. Neurobiol. Dis. 30 (2008) 212-220
11. Georganopoulou D.G. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 1173-2276
12. Glabe C.G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283 (2008) 29639-29643
13. Haes A.J., Chang L., Klein W.L., and Van Duyne R.P. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J. Am. Chem. Soc. 127 (2005) 2264-2271
14. Huang X., Atwood C.S., Moir R.D., Hartshorn M.A., Tanzi R.E., and Bush A.I. Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. J. Biol. Inorg. Chem. 9 (2004) 954-960
15. Jao S.C., Ma K., Talafous J., Orlando R., and Zagorski M.G. Trifluoroacetic acid pretreatment reproducibly disaggregates the amyloid beta-peptide. Amyloid-Int. J. Exp. Clin. Invest. 4 (1997) 240-252
16. Kaiser S.M., and Escher B.I. The evaluation of liposome-water partitioning of 8-hydroxyquinolines and their copper complexes. Environ. Sci. Technol. 40 (2006) 1784-1791
17. Kayed R., Sokolov Y., Edmonds B., MacIntire T.M., Milton S.C., Hall J.E., and Glabe C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein mis-folding diseases. J. Biol. Chem. 279 (2004) 46363-46366
18. Kokkoni N., Stott K., Amijee H., Mason J.M., and Doig A.J. N-methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry 45 (2006) 9906-9918
19. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 6448-6453
20. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., Masters C.L., Targum S., Bush A.I., Murdoch R., Wilson J., and Ritchie C.W. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7 (2008) 779-786
21. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
22. LeVine III H. Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal. Biochem. 335 (2004) 81-90
23. LeVine III H. Biotin-avidin interaction-based screening assay for Alzheimer's beta-peptide oligomer inhibitors. Anal. Biochem. 356 (2006) 265-272
24. LeVine III H. Small molecule inhibitors of Abeta assembly. Amyloid 14 (2007) 185-197
25. LeVine III H. Screening for pharmacologic inhibitors of amyloid fibril formation. Methods Enzymol. 309 (1999) 467-476
26. LeVine III H. Soluble multimeric Alzheimer beta(1-40) pre-amyloid complexes in dilute solution. Neurobiol. Aging 16 (1995) 755-764
27. Necula M., Kayed R., Milton S., and Glabe C.G. Small-molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 282 (2007) 10311-10324
28. Nichols M.R., Moss M.A., Reed D.K., Lin W.L., Mukhopadhyay R., Hoh J.H., and Rosenberry T.L. Growth of beta-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. Biochemistry 41 (2002) 6115-6127
29. Opazo C., Luza S., Villemagne V.L., Volitakis I., Rowe C., Barnham K.J., Strozyk D., Masters C.L., Cherny R.A., and Bush A.I. Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. Aging Cell. 5 (2006) 69-79
30. K.A. Price, P.J. Crouch, A.R. White, Therapeutic treatment of Alzheimer's disease using metal complexing agents, Recent patents on CNS drug discovery 2 (2007) 180-187.
31. Puzzo D., Privitera L., Leznik E., Fa M., Staniszewski A., Palmeri A., and Arancio O. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 28 (2008) 14537-14545
32. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R.E., and Masters C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60 (2003) 1685-1691
33. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192 (2008) 106-113
34. Simons L.J., Caprathe B.W., Callahan M., Graham J.M., Kimura T., Lai Y., LeVine III H., Lipinski W., Sakkab A.T., Tasaki Y., Walker L.C., Yasunaga T., Ye Y., Zhuang N., and Augelli-Szafran C.E. The synthesis and structure-activity relationship of substituted N-phenyl anthranilic acid analogs as amyloid aggregation inhibitors. Bioorg. Med. Chem. Lett. 19 (2009) 654-657
35. Tickler A.K., Smith D.G., Ciccotosto G.D., Tew D.J., Curtain C.C., Carrington D., Masters C.L., Bush A.I., Cherny R.A., Cappai R., Wade J.D., and Barnham K.J. Methylation of the imidazole sidechains of the Alzheimer's disease amyloid-beta peptide results in abolition of SOD-like structures and inhibition of neurotoxicity. J. Biol. Chem. 280 (2005) 13355-13363
36. Tougu V., Karafin A., and Palumaa P. Binding of zinc(II) and copper(II) to the full-length Alzheimer's amyloid-beta peptide. J. Neurochem. 104 (2008) 1249-1259
37. Urbanc B., Cruz L., Teplow D.B., and Stanley H.E. Computer simulations of Alzheimer's amyloid beta-protein folding and assembly. Curr. Alzheimer Res. 3 (2006) 493-504
38. White A.R., Barnham K.J., and Bush A.I. Metal homeostasis in Alzheimer's disease. Expert Rev. Neurother. 6 (2006) 711-722
39. Yang M., and Teplow D.B. Amyloid beta-protein monomer folding: free-energy surfaces reveal alloform-specific differences. J. Mol. Biol. 384 (2008) 450-464